Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Sunday.

Separately, Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $8.33.

Tonix Pharmaceuticals (TNXP) opened at $3.45 on Friday. Tonix Pharmaceuticals has a 52-week low of $2.85 and a 52-week high of $9.40. The stock has a market capitalization of $26.91, a price-to-earnings ratio of -0.72 and a beta of 2.92.

In other news, Director Ernest Mario sold 10,000 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $3.57, for a total transaction of $35,700.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $35,700. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 48,934 shares of company stock valued at $172,496. 4.00% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Vanguard Group Inc. raised its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 184,377 shares of the company’s stock after acquiring an additional 41,264 shares during the period. Vanguard Group Inc. owned about 2.46% of Tonix Pharmaceuticals worth $799,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 17.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/01/tonix-pharmaceuticals-tnxp-downgraded-by-valuengine.html.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.